Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of SJ04 vs Ovidrel in Healthy Chinese Women
NCT06599528Phase 1Recruiting
- Sponsor
- Suzhou Centergene Pharmaceuticals Co., Ltd.
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of SJ04 in female infertility (2 arms), sponsored by Suzhou Centergene Pharmaceuticals Co., Ltd. Primary endpoints: Area under the plasma concentration versus time curve at Day 8 and Peak Plasma Concentration at Day 8. Started Aug 2024; status: recruiting.
02
Drugs
SJ04
03
Conditions
female infertility
Beyond the preview
Go deeper on NCT06599528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599528.